Tony Berberabe, MPH

A new clinical trial evaluates survival outcomes for recurrent head and neck cancer, comparing surgery with neoadjuvant chemotherapy and immunotherapy.

Explore the evolving landscape of myelodysplastic syndromes management, highlighting personalized therapies and novel treatment strategies for better patient outcomes.

FDA designates OPN-2853 as an orphan drug for myelofibrosis, showing promising results in spleen size reduction and safety in clinical trials.

FDA fast-tracks BNT113, an mRNA immunotherapy, for treating HPV16+ head and neck cancer, enhancing immune responses alongside pembrolizumab.

The FDA reviews ropeginterferon alfa-2b-njft for essential thrombocythemia, showing promising efficacy in clinical trials for patients.

Emerging evidence of the benefit of antibody-drug conjugates in diffuse large B-cell lymphoma continues to make a strong case for the agents to be used in earlier lines of therapy.

A novel ctDNA assay identifies high-risk triple-negative breast cancer patients post-surgery, highlighting its potential as a crucial prognostic tool.

XmAb819 shows promising antitumor activity and manageable safety in clear cell renal cell carcinoma patients, highlighting its potential in future therapies.

Immunotherapy shows significant survival benefits for metastatic chromophobe renal cell carcinoma patients with sarcomatoid features, suggesting a potential predictive biomarker.

New data from the SEQUOIA trial highlights the effectiveness of zanubrutinib and venetoclax in achieving high progression-free survival rates in CLL/SLL patients.

Lisaftoclax shows promising efficacy and safety in treating relapsed/refractory CLL/SLL, achieving a 62.5% response rate and 23.89 months progression-free survival.

New research from ESMO 2025 reveals significant survival benefits of intensified androgen blockade over traditional therapies for advanced prostate cancer.

A study reveals cabozantinib plus nivolumab shows a 71% response rate in fumarate hydratase-deficient renal cell carcinoma, promising survival outcomes.

Explore the evolving role of medical oncologists in treating non–muscle invasive bladder cancer with innovative immunotherapy options and trial insights.

Research highlights promising advancements in renal cell carcinoma treatments, focusing on HIF-2α inhibitors and combination therapies for improved patient outcomes.

Recent trials at ESMO Congress 2025 clarify treatment options for metastatic renal cell carcinoma, highlighting promising combinations and emerging therapies.

Novel approaches in MDS focus on HMA doublets, but transplant remains the only curative option to date.

The identification of biomarkers in frontline diffuse large B-cell lymphoma (DLBCL) is ramping up with interest in exploring cell of origin.

Novel therapies, combinations, and investigational treatments are expanding options and show promise in locally advanced metastatic pancreatic cancer.

Sirexatamab combined with bevacizumab shows promise in improving survival for DKK1-high metastatic colorectal cancer patients, according to recent trial results.

New research reveals enzalutamide combined with leuprolide significantly enhances survival rates in high-risk prostate cancer patients, setting a new standard of care.

New research suggests using mpMRI for bladder cancer staging improves survival rates, potentially changing standard diagnostic practices.

Acalabrutinib combined with lenalidomide and rituximab shows promising results as a frontline treatment for follicular lymphoma, achieving high response rates.

Emerging CAR T-cell therapies, like DuoCAR20.19.22-D95, show promise in overcoming challenges in treating relapsed B-cell malignancies.

Explore the latest advancements in DLL3-targeted therapies for small cell lung cancer, showcasing promising trial results and treatment options.

Combination therapy with relatlimab and nivolumab enhances treatment-free survival in advanced melanoma, offering promising outcomes over monotherapy.

Adoptive cell therapy with tumor-infiltrating lymphocytes shows promise for advanced melanoma patients unresponsive to existing treatments, offering tailored immunotherapy options.